Candel Therapeutics, Inc. CADL 深 沪
交易中 02-03 09:52:33 美东时间
6.0175
+0.148
+2.51%
华盛通- 最 高6.0175
- 今 开5.91
- 成交量 2.22万股
- 最 低 5.865
- 昨 收 5.87
- 总市值 3.30亿
- 52周最高 13.68
- 市盈率 静 --
- 换手率 0.04%
- 52周最低 4.25
- 委 比 0.00%
- 总股本 5489.51万
- 历史最高 14.78
- 量 比 2.51
- 振 幅 2.60%
- 历史最低 0.66
- 每 手 1
- 风险率 1.32%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Diamond Hill Investment Group, Rhythm Pharmaceuticals, Vail Resorts And Other Big Stocks Moving Higher On Thursday
U.S. stocks were mixed, with the Dow Jones gaining more than 600 points on Thur...
2025-12-12 01:18
美股大行评级 | 潜在涨幅2566.67%！Ascendiant Capital上调GRI Bio目标价至36美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从35美元升至36美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.75美元升至8美元
2025-12-09 10:32
Stephens & Co. Reiterates Overweight on Candel Therapeutics, Maintains $15 Price Target
Stephens & Co. analyst Sudan Loganathan reiterates Candel Therapeutics (NASDAQ:CADL) with a Overweight and maintains $15 price target.
2025-12-08 22:03
Candel Therapeutics To Present Data About Solid Tumors At Society For Immunotherapy Of Cancer In Maryland
Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company developing multimodal biological immunotherapies to help patients fight cancer, today announced it will deliver
2025-11-04 22:03
美股大行评级 | 上调！苹果、亚马逊、Amkor Tech、Cadence、Confluent、卡特、通用动力等获多家上调目标价
今日重点评级关注：HC Wainwright & Co.：维持PepGen"买入"评级，目标价从12美元升至18美元；Piper Sandler：维持Prothena Corp"超配"评级，目标价从15美元升至36美元
2025-10-29 09:25
EXCLUSIVE: Trinity Capital's New Loan Fuels Bobbie's Mission To Set New US Infant Nutrition Standards
Trinity Capital Inc. announced a financing agreement with Bobbie, an organic infant nutrition company, to boost production capacity and ensure wider distribution of its products.
2025-10-23 19:31
美股大行评级 | 富国银行上调苹果目标价升至290美元；"卖出"！花旗下调NuScale Power、阿特斯太阳能评级
今日重点评级关注：摩根大通：维持Cogent Biosciences"超配"评级，目标价从30美元升至44美元；Piper Sandler：维持Vital Energy"中性"评级，目标价从16美元升至30美元
2025-10-22 10:10
Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board
Candel Therapeutics appoints Bali Pulendran, Ph.D., a leading expert in systems immunology, to its Research Advisory Board. His加入 will support the advancement of Candel's viral immunotherapy candidates, CAN-2409 and CAN-3110, targeting solid tumors and recurrent high-grade glioma, respectively. With a proven track record in human immunology, Pulendran's expertise will enhance the development of innovative therapies to combat cancer across multipl...
2025-10-16 12:05
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Strata Skin Sciences (NASDAQ:SSKN) shares increased by 44.9% to $2.23 ...
2025-10-15 01:06
Candel Therapeutics Secures $130M Loan Facility To Fund Phase 3 Trial And Advance Cancer Pipeline
$50 million drawn down at closing, with access to up to an additional $80 millionStrengthens Company's financial position; enables initiation of phase 3 clinical trial of CAN-2409 in non-small cell lung cancer
2025-10-14 20:14
